LCA Immunohistochemistry at Test Zone Diagnostic Center

LCA Immunohistochemistry at Test Zone Diagnostic Center is a highly specialized diagnostic pathology investigation used to identify the presence of Leukocyte Common Antigen (LCA), also scientifically classified as CD45. This cell-surface glycoprotein is expressed almost exclusively on cells of hematolymphoid origin, including T-lymphocytes, B-lymphocytes, granulocytes, monocytes, and histiocytes. In modern clinical oncology and surgical pathology, distinguishing between different types of poorly differentiated malignant tumors is one of the most significant diagnostic challenges. When a tumor is highly undifferentiated, standard hematoxylin and eosin (H&E) staining may only reveal sheets of pleomorphic round blue cells, making it impossible to determine whether the neoplasm is a carcinoma, sarcoma, melanoma, or lymphoma. LCA Immunohistochemistry at Test Zone Diagnostic Center serves as the primary diagnostic gateway to resolve this clinical dilemma. By utilizing highly specific monoclonal antibodies that bind to the CD45 antigen on the surface of lymphoid cells, this advanced test allows pathologists to confirm or rule out a hematolymphoid lineage with exceptional sensitivity and specificity. The test is performed on formalin-fixed paraffin-embedded (FFPE) tissue sections obtained via surgical biopsy, core needle biopsy, or fine-needle aspiration. The diagnostic value of this test is immense, as the therapeutic management, prognosis, and clinical pathway for a patient with lymphoma are vastly different from those with carcinoma or sarcoma. Accurate identification of LCA expression ensures that patients receive the correct targeted therapies, chemotherapy regimens, or surgical interventions, thereby optimizing clinical outcomes and preventing inappropriate treatment protocols.

Clinical Procedure: What to Expect

Patient Preparation

Because LCA Immunohistochemistry is performed on tissue specimens that have already been extracted from the patient, there is no direct physical preparation required for the immunohistochemical staining itself. However, the preparation guidelines for the patient depend entirely on the primary surgical or biopsy procedure used to obtain the tissue specimen. If the biopsy has not yet been performed, patients must follow specific clinical instructions. For biopsies requiring local or general anesthesia, patients are typically advised to fast for 6 to 8 hours prior to the procedure. It is crucial to inform the referring physician and the clinical team at Test Zone Diagnostic Center about all current medications, especially anticoagulants, antiplatelet agents, or non-steroidal anti-inflammatory drugs (NSAIDs), as these may need to be temporarily discontinued to minimize the risk of bleeding. If the patient is submitting a pre-existing paraffin block or unstained slides obtained from another healthcare facility for a second opinion or specialized IHC testing, they must ensure that the specimen is accompanied by the original histopathology report, clinical history, and relevant radiological findings. Proper documentation of the anatomical site of the biopsy is essential for accurate pathological correlation.

During the Procedure

The laboratory phase of LCA Immunohistochemistry at Test Zone Diagnostic Center involves a series of highly controlled, automated steps designed to ensure maximum staining quality and diagnostic accuracy. Once the tissue biopsy is received, it undergoes fixation in 10% neutral buffered formalin to preserve cellular architecture and prevent autolysis. The tissue is then processed, embedded in paraffin wax, and sectioned into ultra-thin slices of approximately 3 to 4 microns using a high-precision microtome. These sections are mounted onto specially charged glass slides to prevent tissue detachment during subsequent processing. The slides undergo deparaffinization and rehydration through a series of graded alcohols. To expose the target CD45 epitopes that may have been masked during formalin fixation, a process called Heat-Induced Epitope Retrieval (HIER) is performed using specialized buffer solutions under controlled temperature conditions. Next, the slides are incubated with primary monoclonal antibodies directed specifically against LCA. After thorough washing, a secondary detection system containing an enzyme conjugate (such as horseradish peroxidase) is applied, followed by the addition of a chromogen substrate, typically diaminobenzidine (DAB). This reaction produces a highly visible, insoluble brown precipitate at the site of antigen-antibody binding on the cell membrane. The slides are counterstained with hematoxylin to visualize cellular nuclei, dehydrated, cleared, and coverslipped. A consultant pathologist then examines the slides under a high-resolution light microscope, evaluating the staining intensity, cellular localization, and percentage of positive cells relative to positive and negative laboratory controls.

When is an LCA Immunohistochemistry Performed?

Differential Diagnosis of Undifferentiated Malignant Tumors

Physicians request LCA Immunohistochemistry when a patient presents with a rapidly growing, poorly differentiated tumor that cannot be categorized using routine microscopic evaluation. When a biopsy specimen consists of highly atypical, undifferentiated cells, it is clinically critical to determine the lineage of the tumor. LCA positivity immediately points toward a hematolymphoid malignancy, such as lymphoma or leukemia, while LCA negativity directs the diagnostic search toward carcinomas, melanomas, or sarcomas. This differentiation is the cornerstone of oncological workups, as it dictates the entire subsequent diagnostic panel and therapeutic strategy.

Evaluation of Persistent Lymphadenopathy

Persistent, unexplained enlargement of the lymph nodes (lymphadenopathy) in the cervical, axillary, inguinal, or mediastinal regions is a primary clinical indication for a biopsy and subsequent LCA testing. When patients present with systemic symptoms such as fever, night sweats, and unexplained weight loss alongside lymphadenopathy, a biopsy is performed to rule out lymphoma. LCA Immunohistochemistry is utilized to confirm that the atypical cellular infiltrates within the lymph node architecture are indeed of lymphoid origin, helping to differentiate reactive lymphoid hyperplasia from malignant lymphoma.

Classification of Hematologic Malignancies

In cases where a hematolymphoid malignancy has been suspected or partially identified, LCA Immunohistochemistry is performed as part of a comprehensive antibody panel to classify the disease. While LCA confirms the leukocyte origin, it is run in conjunction with other markers like CD3, CD20, CD30, and CD15 to further subclassify the tumor into B-cell lymphoma, T-cell lymphoma, or Hodgkin lymphoma. This precise classification is vital because the treatment protocols for these subcategories differ significantly.

Investigation of Extranodal Masses

Lymphomas do not always originate or remain confined to the lymph nodes; they can present as primary extranodal masses in organs such as the gastrointestinal tract, skin, thyroid, brain, or soft tissues. When a biopsy is taken from an atypical mass in an extranodal site, pathologists perform LCA Immunohistochemistry to determine if the mass is an extranodal lymphoma (such as Mucosa-Associated Lymphoid Tissue lymphoma) or a primary epithelial or mesenchymal tumor of that specific organ.

Distinguishing Inflammatory Infiltrates from Neoplasms

In many chronic inflammatory conditions, tissue biopsies can show dense, atypical lymphocytic infiltrates that closely mimic low-grade lymphomas. Pathologists utilize LCA Immunohistochemistry to highlight the distribution, density, and morphology of the leukocyte population. This helps in assessing whether the cells represent a polyclonal, benign inflammatory response or a monoclonal, neoplastic proliferation, especially when combined with molecular clonality studies.

What Does an LCA Immunohistochemistry Detect?

LCA Immunohistochemistry is designed to detect the presence or absence of the CD45 antigen on cell membranes. The clinical findings and diagnostic interpretations include:

• Strong Membranous Positivity: Confirms the presence of hematolymphoid cells, strongly supporting a diagnosis of lymphoma or leukemia.
• Diffuse Large B-Cell Lymphoma (DLBCL) Detection: Shows intense, diffuse membranous LCA staining in large atypical lymphoid cells.
• Follicular Lymphoma Identification: Detects positive LCA expression within neoplastic follicles and interfollicular regions.
• Chronic Lymphocytic Leukemia (CLL) Confirmation: Reveals uniform, positive LCA staining in small, mature-looking lymphocytes.
• Peripheral T-Cell Lymphoma Detection: Shows positive LCA expression in atypical T-lymphocytes, confirming lymphoid lineage.
• Anaplastic Large Cell Lymphoma (ALCL) Evaluation: Demonstrates variable or sometimes weak LCA expression, requiring correlation with CD30 and ALK markers.
• Hodgkin Lymphoma Differentiation: Classic Reed-Sternberg cells are typically negative or only weakly/partially positive for LCA, which is a key diagnostic clue when surrounding background lymphocytes stain strongly positive.
• Multiple Myeloma / Plasma Cell Neoplasm Assessment: Plasma cells often show down-regulated or negative LCA expression, which helps differentiate them from other lymphoid cells.
• Exclusion of Epithelial Carcinoma: A negative LCA result in an undifferentiated tumor helps rule out carcinomas, directing the panel toward cytokeratins.
• Exclusion of Malignant Melanoma: Negative LCA staining helps rule out melanoma, prompting further testing with S100, Melan-A, or HMB45.
• Exclusion of Mesenchymal Sarcoma: Negative LCA staining helps rule out sarcomas, directing the pathologist to evaluate vimentin, desmin, or SMA.
• Detection of Inflammatory Myofibroblastic Tumor Infiltrates: Highlights the background inflammatory leukocytes while the neoplastic spindle cells remain LCA negative.
• Identification of Lobular Carcinoma vs. Lymphoma: Differentiates single-file infiltrating lobular breast carcinoma (LCA negative) from lymphoma (LCA positive).
• Evaluation of Thymoma vs. Lymphoma: Helps distinguish thymic epithelial cells (LCA negative) from the abundant background thymocytes (LCA positive).
• Assessment of Brain Biopsies: Differentiates primary central nervous system lymphoma (LCA positive) from glioblastoma or metastatic carcinoma (LCA negative).
• Detection of Lymphoid Infiltrates in Bone Marrow: Evaluates bone marrow trephine biopsies for involvement by leukemia or lymphoma.
• Identification of Myeloid Sarcoma: Shows positive or variable LCA expression in extramedullary myeloid tumor masses.
• Evaluation of Gastric Biopsies: Differentiates Helicobacter pylori-associated gastritis (reactive LCA positive infiltrates) from gastric MALT lymphoma.
• Assessment of Skin Biopsies: Differentiates cutaneous T-cell lymphoma (Mycosis Fungoides) from inflammatory dermatoses.
• Detection of Lymphoepithelioma-like Carcinoma: Highlights the prominent, non-neoplastic lymphoid stroma (LCA positive) surrounding the nests of carcinoma cells (LCA negative).

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that waiting for histopathology and immunohistochemistry results can be an anxious time for patients and their families. Because immunohistochemistry requires meticulous tissue processing, antigen retrieval, multiple incubation steps, and expert microscopic evaluation, the turnaround time for LCA Immunohistochemistry typically ranges from 3 to 5 working days. This timeline ensures that every slide undergoes rigorous quality control and is interpreted by a highly qualified consultant pathologist. Once the report is finalized and signed off, patients are immediately notified via SMS. Reports can be accessed and downloaded directly from the secure online portal of Test Zone Diagnostic Center, or collected in person from the center. We also provide the option to have the reports emailed directly to the referring oncologist or physician to facilitate prompt clinical decision-making.

LCA Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Lymph Nodes	Normal architecture with LCA positive lymphocytes in follicles and paracortex	Effacement of architecture by sheets of atypical LCA positive neoplastic cells (Lymphoma)
Epithelial Tissues	LCA negative epithelial cells; rare intraepithelial lymphocytes	LCA negative tumor cells with nested or glandular patterns (Carcinoma)
Mesenchymal Tissues	LCA negative stromal and connective tissue cells	LCA negative spindle or pleomorphic cells (Sarcoma)
Melanocytic Lesions	LCA negative melanocytes	LCA negative highly atypical cells with melanin pigment (Melanoma)
Reed-Sternberg Cells	Not present	Large multinucleated cells that are LCA negative or weakly positive in a background of LCA positive cells
Bone Marrow Trephine	Normal trilineage hematopoiesis with scattered LCA positive cells	Hypercellular marrow packed with LCA positive blasts or lymphoid aggregates
Inflammatory Infiltrates	Polyclonal, organized distribution of LCA positive inflammatory cells	Monoclonal, dense, destructive sheets of LCA positive cells

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for LCA Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists with extensive experience in oncopathology and immunohistochemistry.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate support throughout the diagnostic process.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to strict international quality control standards for all immunohistochemical staining procedures.
• Professional Reporting: Our reports provide detailed, comprehensive diagnostic insights, including antibody panel correlations, to assist oncologists in treatment planning.
• Modern Diagnostic Approach: We utilize advanced automated staining platforms that minimize human error and ensure highly reproducible staining quality.
• Comfortable Environment: Our diagnostic center is designed to provide a clean, safe, and welcoming environment for all patients and visitors.
• Convenient Location: Easily accessible location with ample parking and streamlined reception services for hassle-free sample submission.
• Commitment to Accurate Diagnosis: We are dedicated to delivering precise, evidence-based diagnostic results that form the reliable foundation of your medical care.